SurGenTec
$704.8K 249 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Napo Pharmaceuticals Inc
Napo Pharmaceuticals Inc reported $704,817.67 across General Payments, Research, and Ownership to 1,430 physicians and teaching hospitals across 1,508 transactions.
- $704.8K Above-median payer
- All-tracks total
- 1,508 Top quartile volume
- Transactions
- 1,430 Top quartile reach
- Recipients
- −$9.8K
- General Payments vs PY2023
Napo Pharmaceuticals Inc reported $704,817.67 across all CMS Open Payments tracks (General + Research + Ownership) to 1,430 physicians and teaching hospitals in Program Year 2024 - ranking #691 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $189,647.62, averaging $492.88 per recipient.
How Napo Pharmaceuticals Inc's $704.8K all-tracks total breaks down
Napo Pharmaceuticals Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
16/100
Transaction volume
F
21/100
Physician reach
F
21/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer napo-pharmaceuticals-inc Napo Pharmaceuticals Inc
$704.8K · #691/1,925 · 0.0% industry · PY2024
- TOT $704.8K
- RANK #691
- SHARE 0.0%
- TXN 1,508
- RCP 1,430
- CAT 3
- GEN $189.6K
- ΔGEN −$9.8K
- TOP1 12.1%
- PY 2024
Volume peers
Nearest volume peer: SurGenTec ($704.8K)
Napo Pharmaceuticals Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Napo Pharmaceuticals Inc's CMS-reported General Payments decreased by $9.8K (−4.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NAPO PHARMACEUTICALS INCPY2023: NAPO PHARMACEUTICALS INCPY2024: Napo Pharmaceuticals Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $199,443.20
- PY2024
- $189,647.62
What the Data Shows for Napo Pharmaceuticals Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Napo Pharmaceuticals Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $93.7K across 31 transactions, 49.4% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Napo Pharmaceuticals Inc made 3 types of general payments. "Consulting Fee" is the largest category at $93.7K, 49.4% of General Payments.
How Napo Pharmaceuticals Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $93.7K | 31 | 49.4% |
| Compensation for Faculty or Speaker (Medical Education) | $62.2K | 22 | 32.8% |
| Food and Beverage | $33.8K | 1,377 | 17.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $86,469.73 (45.6%) of $189,647.62 in this company's General Payments records across 603 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Napo Pharmaceuticals Inc
The five named recipients with the highest reported General Payments from this company
- 1
Elie Schochet
$23,017.49 across 8 reported transactions
- 2
Robin Hardwicke
$21,843.73 across 19 reported transactions
- 3
Sandra Swain
$16,077.10 across 5 reported transactions
- 4
Pablo Okhuysen
$13,454.31 across 2 reported transactions
- 5
Lee Schwartzberg
$12,077.10 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Napo Pharmaceuticals Inc ranks #691 of 1,925 by total payments (top 36% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,210 of 1,838 by HHI (bottom 34% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Eagle Pharmaceuticals, Inc. : $177.1K total payments, HHI 640
- EyePoint Pharmaceuticals US, Inc. : $827.8K total payments, HHI 640
- Jenavalve Technology, Inc. : $869.0K total payments, HHI 640
- BioMarin Pharmaceutical Inc. : $3.0M total payments, HHI 639
- Roche Molecular Systems, Inc. : $3.5M total payments, HHI 638
- Aroa Biosurgery Incorporated : $591.0K total payments, HHI 637
- Napo Pharmaceuticals Inc (this company) : $189.6K total payments, HHI 636
- Arthrosurface Incorporated : $1.8K total payments, HHI 636
- B. Braun Interventional Systems Inc. : $271.8K total payments, HHI 635
- Aesculap, Inc. : $921.5K total payments, HHI 634
- Ultragenyx Pharmaceutical Inc. : $454.6K total payments, HHI 634
- Pulmonx Corporation : $847.7K total payments, HHI 633
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Napo Pharmaceuticals Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Napo Pharmaceuticals Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Napo Pharmaceuticals Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Calvary Spine, LLC
$703.2K 0 recipients
Compare payment profiles
Day One Biopharmaceuticals
$703.0K 191 recipients
Compare payment profiles
Kuros Biosciences USA, Inc
$711.3K 1,447 recipients
Compare payment profiles
Scilex Pharmaceuticals Inc.
$715.7K 19,348 recipients
Compare payment profiles
ZOLL Respicardia, Inc.
$718.3K 1,630 recipients
Compare payment profiles
Put this to use
Napo Pharmaceuticals Inc ranks #691 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Napo Pharmaceuticals Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.